Circulating pDCs from patients with melanoma have been found to express higher amounts of CCR6 and CXCR4, while their corresponding ligands CCL20 and CXCL12 are expressed on melanoma cells, suggesting that the CCR6/CCL20 and CXCR4/CXCL12 axes promote pDC migration from blood to melanoma foci (27, 34, 50, 51). Here, CXCR4 is linked to melanoma.